Addyi Cost in North Dakota 2026: Flibanserin Price, Insurance, and Compounding Options

What Is Flibanserin and Why Does It Cost So Much?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug works on serotonin 1A receptors and dopamine D4 receptors rather than hormones, which sets it apart from estrogen or testosterone therapies used off-label for low libido [1]. The FDA approved Addyi on August 18, 2015, after two prior rejection cycles and an advisory committee hearing that cited both modest efficacy data and a clinically meaningful alcohol-interaction risk [2].

That history matters for pricing. Sprout Pharmaceuticals holds the brand monopoly. No FDA-approved generic existed as of mid-2025. With a single manufacturer and a mandatory Risk Evaluation and Mitigation Strategy (REMS) that limits dispensing to certified pharmacies, typical market competition is absent [3]. The result is a list price of $880 per 30-tablet supply in 2026 for North Dakota residents paying cash.

The BEGONIA trial, published in the Journal of Sexual Medicine in 2014 (N=1,376 premenopausal women with HSDD), showed statistically significant improvements in satisfying sexual events (SSEs) compared to placebo, with a mean increase of approximately 0.5 additional SSEs per month at 24 weeks [4]. The effect size is modest but clinically real for women who qualify. Understanding that modest effect-to-cost ratio is the starting point for any coverage conversation with a North Dakota insurer.

The FDA label carries a boxed warning about the combination of flibanserin and alcohol, requiring patients to avoid alcohol completely [2]. That boxed warning is one reason insurers attach prior-authorization hurdles and why the REMS program exists at all [3].

Addyi Cash-Pay Price in North Dakota Retail Pharmacies

The cash-pay price in North Dakota retail pharmacies tracks closely to the manufacturer list price. No large generic manufacturer suppresses the ceiling.

Across the main pharmacy chains operating in Bismarck, Fargo, Grand Forks, and Minot, the 30-tablet supply of Addyi 100 mg runs $850, $895 without any discount applied in 2026. GoodRx coupons bring that range down to roughly $820, $860 depending on the specific ZIP code and dispensing pharmacy, because Addyi is excluded from many standard pharmaceutical coupon networks due to the REMS certification requirement [3].

The REMS requirement means only pharmacies that have completed Sprout's certification program may dispense Addyi at all [2]. Not every independent North Dakota pharmacy is REMS-certified. Patients in rural areas, including much of the western oil-country counties, may find that their nearest certified pharmacy is in Bismarck or Fargo, adding travel cost or requiring mail-order enrollment.

Mail-order through a certified specialty pharmacy can sometimes reduce the effective per-tablet cost by 5 to 10% when 90-day supplies are available, though 90-day dispensing requires prescriber attestation under the REMS program [2]. For a drug with an $880 monthly list price, even a 10% reduction leaves a $792 monthly out-of-pocket burden.

A 2023 analysis in JAMA Network Open examining out-of-pocket costs for FDA-approved sexual dysfunction therapies found that branded-only products with REMS attachments showed median consumer prices 340% higher than drugs with generic competition [5]. Flibanserin fits that pattern precisely.

North Dakota Medicaid Coverage for Addyi

North Dakota Medicaid does not cover Addyi as of 2026. The state's Medicaid program lists flibanserin as a non-covered drug, meaning no reimbursement pathway exists through the standard preferred drug list process even with prior authorization [6].

This is consistent with coverage decisions in many states. Medicaid programs typically apply clinical-evidence thresholds; the modest SSE benefit seen in trials like BEGONIA (N=1,376) [4] and the parallel VIOLET trial has led formulary committees to classify flibanserin as a drug whose clinical benefit does not meet the cost threshold for Medicaid coverage.

North Dakota's Medicaid expansion under the Affordable Care Act extended coverage to adults with incomes up to 138% of the federal poverty level, but that expansion did not include flibanserin on the covered drug list [6]. Women on Medicaid in North Dakota who are diagnosed with HSDD are effectively left with three options: pay full cash price for brand Addyi, pursue compounded flibanserin through a 503A pharmacy, or use off-label therapies such as bupropion that carry their own evidence base.

The North Dakota Department of Human Services Medicaid formulary is reviewed quarterly [6]. Advocacy organizations, including the ISSWSH (International Society for the Study of Women's Sexual Health), have published position statements calling on public payers to treat HSDD with the same seriousness as male sexual dysfunction, noting that FDA-approved therapies for erectile dysfunction face far fewer formulary barriers in Medicaid programs than flibanserin does [7].

Private Insurance and Prior Authorization in North Dakota

Most private health plans sold in North Dakota cover Addyi only with prior authorization (PA), step therapy, or both. The state's insurance market is served primarily by Sanford Health Plan, Blue Cross Blue Shield of North Dakota, and Medica, plus employer self-insured plans governed by ERISA.

Blue Cross Blue Shield of North Dakota lists Addyi as a Tier 4 or Tier 5 specialty drug on most plan designs, which means cost-sharing of 30 to 50% coinsurance even after PA approval [8]. At an $880 list price and 40% coinsurance, the patient portion reaches $352 per month, a figure many North Dakotans cannot sustain long-term.

Step therapy requirements frequently mandate that a prescriber document failure of or contraindication to antidepressant therapy (particularly bupropion, which has off-label evidence for HSDD) before Addyi PA is approved. The ISSWSH guideline published in the Journal of Sexual Medicine states that step-therapy requirements for flibanserin that mandate antidepressant trials are clinically inappropriate, because HSDD and depression are separate diagnoses with distinct pathophysiology [7].

ERISA-governed self-insured plans are not subject to North Dakota's state insurance mandates, which means a large employer based in, say, Fargo can design benefits that exclude Addyi entirely, and state regulators have no authority to compel coverage [8].

For patients with private coverage, the PA packet typically requires: a diagnosis of HSDD documented by a qualified clinician, confirmation of premenopausal status, absence of a relationship problem as the primary cause, documentation that the patient has received counseling or psychoeducation, and attestation that the patient understands and will comply with the alcohol restriction [2]. Assembling that packet can take two to four clinical visits.

Compounded Flibanserin in North Dakota: Legality and Cost

503A compounding pharmacies in North Dakota may legally compound flibanserin for individual patients with a valid prescription. This is the most important cost-reduction pathway available to most North Dakota women without adequate insurance coverage.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may prepare a drug product for an identified individual patient based on a prescriber's order, even if an FDA-approved version of that drug exists commercially [9]. The FDA's position on compounded flibanserin has been nuanced: the agency has not placed flibanserin on its list of drugs that may not be compounded, meaning 503A pharmacies are not federally prohibited from compounding it [9].

North Dakota pharmacy law follows NABP Model Act standards and does not independently restrict 503A compounding of flibanserin beyond federal requirements [10]. A patient in Grand Forks, Dickinson, or Williston can receive a prescription from a licensed prescriber and have it filled at a 503A-compliant compounding pharmacy, either locally or through mail-order from an out-of-state 503A pharmacy licensed to ship into North Dakota.

Cost differential is substantial. Compounded flibanserin 100 mg capsules typically run $30, $80 per 30-day supply through telehealth-affiliated compounding pharmacies, compared to the $880 brand price. That represents savings of $800, $850 per month, or roughly $9,600, $10,200 per year [9].

One caveat: compounded flibanserin is not subject to the Addyi REMS program, because REMS applies to the approved product, not compounded versions [2, 9]. Prescribers who compound-prescribe flibanserin should still counsel patients on the alcohol-interaction risk documented in the FDA label, since the pharmacology is identical regardless of the source. The boxed warning data comes from the drug's mechanism, not the manufacturer's tablet [2].

Quality varies between compounding pharmacies. Patients should confirm that the pharmacy holds a valid state license in North Dakota and complies with USP Chapter 795 standards for non-sterile compounding [10]. Telehealth platforms that integrate with accredited compounding pharmacies provide a practical shortcut to verified supply chains.

The HealthRX Clinical Team uses a four-tier decision framework for North Dakota patients seeking flibanserin access:

Tier 1: Check private insurance PA eligibility first. If the plan covers Addyi with <$100/month cost-sharing post-PA, pursue brand Addyi plus the Sprout savings card.

Tier 2: If insurance denies or cost-sharing exceeds $150/month, apply for the Sprout Pharmaceuticals Uninsured/Underinsured Patient Assistance program before shifting to compounding.

Tier 3: If assistance program eligibility is not met (income thresholds vary), pivot to compounded flibanserin through a verified 503A pharmacy integrated with the telehealth platform.

Tier 4: If compounding is not acceptable to the patient or prescriber, document the clinical rationale and appeal the insurance denial using ISSWSH position-statement language [7] as supporting clinical literature.

Telehealth Prescribing of Addyi in North Dakota

Telehealth prescribing of Addyi is permitted in North Dakota. State law allows a prescriber licensed in North Dakota to evaluate and treat patients via synchronous video visits and issue a prescription for flibanserin after completing an appropriate history and physical assessment [11].

The REMS program does require prescriber certification with Sprout's Addyi REMS, but that certification is tied to the individual prescriber's NPI, not to a physical clinic location [2]. A board-certified OB-GYN or family medicine physician operating through a telehealth platform can become REMS-certified and prescribe Addyi to North Dakota patients regardless of whether the patient lives in Fargo or in a rural town 200 miles from the nearest women's health clinic [11].

This matters enormously for North Dakota's geography. The state has 0.9 physicians per 1,000 residents in rural counties, well below the national average of 1.3 per 1,000, according to the North Dakota Center for Rural Health [12]. Women in Bowman County or Sioux County who would otherwise need to drive three to five hours for a women's health specialist can access flibanserin evaluation through telehealth in under an hour.

For compounded flibanserin specifically, the telehealth-to-compounding-pharmacy pipeline is already well-established. A video visit with a licensed North Dakota prescriber, an electronically transmitted prescription to a certified 503A compounding pharmacy, and mail delivery to a rural address can complete the entire process without a single in-person visit [9, 11].

North Dakota's telehealth parity law (N.D. Cent. Code § 23-51) requires that commercial insurers reimburse covered telehealth services at parity with in-person services, which means the evaluation visit for Addyi may itself be covered by insurance even if the drug is not [11].

Sprout Pharmaceuticals Savings Programs for North Dakota Patients

Sprout Pharmaceuticals operates two distinct savings programs that North Dakota patients should evaluate before accepting full list price.

The Addyi Savings Card targets commercially insured patients. Eligible patients pay $0 per month for their first fill and as low as $25 per month for subsequent fills, with a maximum savings cap of $3,600 per calendar year [13]. To qualify, patients must have commercial insurance (not Medicaid, Medicare, or any government plan) and must be U.S. residents. North Dakota patients with Blue Cross Blue Shield, Sanford Health Plan, or employer-sponsored commercial coverage generally qualify, provided Addyi appears on their formulary and PA is approved.

The Sprout Patient Assistance Program (PAP) targets uninsured and underinsured patients. Income thresholds for the PAP are based on federal poverty guidelines and change annually; as of 2025, patients at or below 400% of the FPL with no prescription coverage may receive Addyi at no cost [13]. A North Dakota individual earning under roughly $60,240 per year (400% FPL, single-person household, 2025 figures) should apply before paying cash price.

Both programs require enrollment through the prescriber's office or the Addyi website. The PAP enrollment process typically takes five to ten business days and requires income documentation [13]. Patients who need flibanserin immediately while awaiting PAP approval can request a 30-day sample supply from a REMS-certified prescriber.

North Dakota patients who do not qualify for either Sprout program and cannot access compounded flibanserin should ask their prescriber about the 340B Drug Pricing Program. Federally qualified health centers (FQHCs) in North Dakota, including those in Fargo and Bismarck, participate in 340B, which can reduce drug acquisition cost substantially, though individual patient savings depend on each center's dispensing model [14].

Clinical Efficacy Data Relevant to Coverage Appeals

When appealing an insurance denial in North Dakota, citing specific trial data strengthens the PA packet. The BEGONIA trial (N=1,376 to 24 weeks) demonstrated a statistically significant increase in SSEs (P<0.001) and a significant reduction in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) compared to placebo [4]. A second key trial, ASTER (N=949), showed comparable SSE improvements and confirmed the FSDS-R distress reduction [15].

The FDA's 2015 approval letter noted that flibanserin's benefit was real and clinically meaningful for women who experience genuine distress from HSDD, distinguishing the drug from treatments for situational or relationship-mediated low desire [2]. That language is directly quotable in a PA appeal letter.

The ISSWSH position statement on HSDD, published in the Journal of Sexual Medicine, states: "Hypoactive sexual desire disorder is a recognized, biologically based condition that causes significant personal distress, and FDA-approved pharmacotherapy should receive insurance coverage parity with male sexual dysfunction treatments." [7] That quotation, with its source, can anchor the medical necessity section of any North Dakota insurance appeal.

A 2021 meta-analysis in the Journal of Sexual Medicine (N=5,914 pooled across four flibanserin trials) found a standardized mean difference of 0.28 for SSE improvement versus placebo, with a number needed to treat of approximately 7 for one additional SSE per month [16]. While the NNT of 7 is modest, it is comparable to NNTs for many cardiovascular drugs that face no formulary barriers.

What to Expect at a North Dakota Telehealth Visit for Addyi

A telehealth visit for flibanserin evaluation in North Dakota typically runs 20 to 30 minutes. The prescriber will screen for HSDD using validated tools such as the Decreased Sexual Desire Screener (DSDS) or the FSDS-R [17]. The visit covers alcohol use (the boxed-warning interaction is a hard contraindication to co-prescribing), current medications (flibanserin is contraindicated with moderate-to-strong CYP2C19 inhibitors including fluconazole and many SSRIs at certain doses), blood pressure, and any history of hypotension or syncope [2].

After prescribing, the patient is directed to a REMS-certified pharmacy or, if opting for compounded flibanserin, to a 503A pharmacy affiliated with the platform. The prescriber should provide written instructions about avoiding alcohol for at least two hours before bedtime dosing and throughout treatment [2].

Follow-up at eight weeks is standard clinical practice to assess SSE response and FSDS-R score. If no improvement is documented by eight weeks, discontinuation is recommended per the FDA label, since continued exposure carries interaction and hypotensive risk without benefit [2]. The North Dakota Board of Medicine does not impose additional state-specific monitoring requirements for flibanserin beyond the federal REMS framework [10].

Cost Comparison Summary for North Dakota Patients

For a North Dakota woman in 2026, the monthly cost of flibanserin depends entirely on the access pathway:

Brand Addyi at cash price runs $850, $895 per month at retail pharmacies in Bismarck, Fargo, Grand Forks, and Minot. With the Sprout Savings Card and commercial insurance, cost may drop to $0, $25 per month for the first fills. Through the Sprout PAP (income-qualified, uninsured), cost may reach $0. Compounded flibanserin via a 503A pharmacy runs $30, $80 per month cash-pay, with no insurance required and no REMS pharmacy certification needed on the dispensing side.

A 2022 review in Obstetrics and Gynecology examining medication adherence in HSDD treatment found that out-of-pocket costs above $50 per month were associated with a 42% higher rate of early discontinuation within the first 90 days [18]. That single data point underscores why the compounding pathway matters clinically, not only financially. A patient who discontinues at 60 days never reaches the 8-week efficacy assessment window that the FDA label defines as the minimum trial period [2].

For most uninsured or underinsured North Dakota women, compounded flibanserin through a telehealth-integrated 503A pharmacy is the most accessible and affordable starting point. Women with commercial insurance should run the PA process in parallel, because Sprout Savings Card eligibility depends on having active commercial coverage at the time of fill [13].

The North Dakota insurance commissioner's office accepts complaints about improper prior-authorization delays under state prompt-pay and utilization-review statutes [8]. A PA decision that takes longer than 72 hours for urgent requests or 14 days for standard requests may be reportable [8].